The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study
Matthew S. Davids(Dana-Farber Cancer Institute), John F. Seymour(The Royal Melbourne Hospital), Cathy E. Nolan(Abbott Fund), Sari H. Enschede(AbbVie (United States)), Andrew W. Roberts(The Royal Melbourne Hospital), John M. Pagel(University of Washington), David E. Darden(Abbott Fund), Alison M. Graham(Abbott Fund), Rod Humerickhouse(Abbott Fund), Brenda Chyla(AbbVie (United States)), Brad S. Kahl(UW Health University Hospital), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), Mary Ann Anderson(The Royal Melbourne Hospital), Jianning Yang(AbbVie (United States)), Elisa Cerri(AbbVie (United States)), Todd Busman(Abbott Fund), Lori A. Gressick(AbbVie (United States))
Cited by 40
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k